Valuation: Zymeworks Inc.

Market Cap 1.65B 1.45B 1.35B 1.24B 2.32B 158B 2.35B 16.02B 6.25B 77.97B 6.18B 6.05B 269B P/E 2026 *
19x
P/E 2027 * 108x
Enterprise Value 1.4B 1.23B 1.15B 1.05B 1.97B 134B 2B 13.61B 5.32B 66.26B 5.25B 5.14B 229B EV / Sales 2026 *
4.78x
EV / Sales 2027 * 6.98x
Free-Float
90.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.61%
1 week-3.20%
Current month-12.01%
1 month-4.76%
3 months-19.47%
6 months-1.08%
Current year-12.65%
1 week 22.72
Extreme 22.72
24.24
1 month 21.91
Extreme 21.91
27.41
Current year 21.91
Extreme 21.91
29.75
1 year 11.51
Extreme 11.51
29.75
3 years 6.02
Extreme 6.015
29.75
5 years 4.11
Extreme 4.11
37.19
10 years 4.11
Extreme 4.11
59.03
Manager TitleAgeSince
Chief Executive Officer 63 2022-01-04
Director of Finance/CFO 44 2026-03-31
Chief Tech/Sci/R&D Officer - 2024-11-30
Director TitleAgeSince
Chairman 63 2022-01-04
Director/Board Member 61 2019-05-31
Director/Board Member 52 2020-02-29
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Free

Chief Operating Officer

939 0.0013%
5/13/26 Free

EVP, General Counsel

297,000 0.4027%
5/13/26 Other

EVP, General Counsel

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+0.61%-3.20%+72.54%+215.93% 1.65B
-0.48%+3.29%+53.42%+72.95% 56.19B
-0.27%+0.35%+40.26%+79.88% 54.83B
-2.05%-2.14%+0.75%+413.38% 22.7B
+1.97%-1.16%-21.00%-13.25% 23.04B
-0.21%-0.62%+20.56%-10.90% 20.23B
-1.47%+1.35%+25.38%-30.64% 17.83B
-0.97%-0.59%+33.12%+550.67% 15.65B
+5.29%+1.70%+185.09%+333.94% 15.24B
+0.79%+0.50%+22.39%+184.74% 14.03B
Average +0.30%+0.47%+43.25%+179.67% 24.14B
Weighted average by Cap. -0.01%+1.04%+38.87%+138.56%

Financials

2026 *2027 *
Net sales 293M 257M 240M 220M 413M 28.09B 419M 2.85B 1.11B 13.87B 1.1B 1.08B 47.94B 204M 179M 167M 153M 288M 19.56B 292M 1.98B 775M 9.66B 766M 749M 33.38B
Net income 90.71M 79.74M 74.23M 68.17M 128M 8.7B 130M 882M 345M 4.3B 341M 333M 14.85B 40.67M 35.75M 33.28M 30.57M 57.39M 3.9B 58.15M 396M 155M 1.93B 153M 149M 6.66B
Net Debt -247M -217M -202M -186M -349M -23.7B -353M -2.4B -939M -11.7B -928M -908M -40.45B -223M -196M -182M -167M -315M -21.37B -319M -2.17B -847M -10.55B -837M -819M -36.48B
Logo Zymeworks Inc.
Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.
Employees
243
Date Price Change Volume
26-07-27 US$23.00 +0.61% 259,300
26-07-24 US$22.86 -1.12% 272,376
26-07-23 US$23.12 -1.03% 357,873
26-07-22 US$23.36 -2.87% 388,075
26-07-21 US$24.05 +1.22% 512,933
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
23.00USD
Average target price
39.33USD
Spread / Average Target
+71.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ZYME Stock